These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Gluckman E; Devergie A; Lokiec F Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282 [No Abstract] [Full Text] [Related]
27. [Prevention of graft versus host disease by in vitro immunodepletion of the graft]. Maraninchi D Nouv Rev Fr Hematol (1978); 1985; 27(6):349-50. PubMed ID: 3912729 [No Abstract] [Full Text] [Related]
28. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases. Tolland JP; Devereux C; Jones FC; Bingham EA Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789 [TBL] [Abstract][Full Text] [Related]
29. The use of monoclonal antibodies in human bone marrow transplantation. Neudorf SM; Filipovich AH; Kersey JH Prog Clin Biol Res; 1984; 149():367-77. PubMed ID: 6377327 [No Abstract] [Full Text] [Related]
30. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation--combination protocol of high dose methylprednisolone, prednisolone and methotrexate]. Shinohara Y; Kai S; Misawa M; Fujimori Y; Okamoto T; Kohsaki M; Kanamaru A; Ifuku H; Ohe Y; Hara H Rinsho Ketsueki; 1986 Jan; 27(1):30-5. PubMed ID: 3520045 [No Abstract] [Full Text] [Related]
31. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386 [TBL] [Abstract][Full Text] [Related]
32. Bone marrow transplantation. Current limitations and future utilization. Gardner RV; Gross S J Fla Med Assoc; 1984 May; 71(5):316-20. PubMed ID: 6376695 [No Abstract] [Full Text] [Related]
33. Prevention of graft-versus-host disease after bone marrow and small bowel transplantation by ultraviolet B modulation of bone marrow cells. Chowdhury NC; Jin MX; Hardy MA; Oluwole SF Transplant Proc; 1993 Feb; 25(1 Pt 1):475-6. PubMed ID: 8438384 [No Abstract] [Full Text] [Related]
35. Immunosuppression, graft-versus-host disease, and infection after bone marrow transplantation. Kramer BS; Elfenbein GJ J Fla Med Assoc; 1984 May; 71(5):321-8. PubMed ID: 6429272 [No Abstract] [Full Text] [Related]
36. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation. Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648 [No Abstract] [Full Text] [Related]
37. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Champlin R Exp Hematol; 1995 Oct; 23(11):1148-51. PubMed ID: 7556522 [No Abstract] [Full Text] [Related]
38. Approaches to graft-versus-host disease following bone marrow transplantation in monkeys and man. Dicke KA; Spitzer G; Peters L; Stevens EE; Hendriks W; McCredie tkb Transplant Proc; 1978 Mar; 10(1):217-21. PubMed ID: 416529 [No Abstract] [Full Text] [Related]
39. The influence of the microbial flora on incidence of graft-versus-host disease in human allogeneic bone marrow transplantation. Schmeiser T; Kurrle E; Arnold R; Heit W; Krieger D; Kubanek B; Heimpel H Prog Clin Biol Res; 1985; 181():433-5. PubMed ID: 3895247 [No Abstract] [Full Text] [Related]
40. [1st seminar of the Study Group on Bone Marrow Grafting on immunodepletion in the prevention of the graft-vs-host reaction. Marseilles, France, 4-6 October 1984. Abstracts]. Nouv Rev Fr Hematol (1978); 1985; 27(6):351-75. PubMed ID: 3912730 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]